Myasthenia gravis is a chronic autoimmune disorder that inhibits communication between nerve cells and muscles, causing muscle weakness. It has no cure, but several treatment options can help improve ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis is ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

Please provide your email address to receive an email when new articles are posted on . Two observational studies compared videos of those with myasthenia gravis with healthy controls. A deep learning ...

Please provide your email address to receive an email when new articles are posted on . 12 individuals with generalized myasthenia gravis related their mental and physical health experiences. The ...

THOUSAND OAKS, Calif., March 13, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA ® ...

FDA Approves Treatment for gMG FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), ...

In a recent interview with The American Journal of Managed Care ®, Marla Black Morgan, MD, neurologist with Phoebe Neurology Associates, discussed the findings from her investigation into the ...

Mestinon (pyridostigmine bromide) is a brand-name drug that’s prescribed for myasthenia gravis. Mestinon comes as an oral tablet, extended-release oral tablet, and oral solution. The dosage can vary ...

Myasthenia gravis is a life-long (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

"I'm looking forward to further examining the 52-week MINT data with my colleagues in the neurology community at AAN," said Richard J. Nowak, M.D., M.S., global principal study investigator and ...